BCAL Challenges Genetic Signatures–Microba Deal, While Employee Shares Are Issued
BDX: $0.060 -1.64% · MC: $22M
BCAL Diagnostics, which holds 18.46% of Genetic Signatures, has asked the Takeovers Panel to intervene in Genetic Signatures’ proposed merger with Microba, arguing the deal terms could restrict competing offers and shareholders lack sufficient time and information; the Panel has not decided whether to conduct proceedings. Separately, BCAL issued ordinary shares to employees under its incentive scheme, while performance rights lapsed and options expired.

Comments